EpimAb

Biotech

Almirall signs $210M deal with EpimAb to develop bispecifics

The money will give Almirall access to EpimAb Biotherapeutics’ Fabs-In-Tandem Immunoglobulin platform .

James Waldron Oct 12, 2023 9:55am

Shanghai skyline

EpimAb reels in $120M to propel 3 clinical-stage bispecifics

Mar 22, 2021 7:00pm

Philadelphia city skyline

BIO: EpimAb bags $74M to build bispecifics pipeline

Jun 5, 2019 12:00am